Six CAR-T cell therapies have been approved by the FDA over the last six years to treat various types of blood cancers. While modulating T cells represents a monumental step forward in cancer treatment, challenges remain for successfully treating more patients with this approach. One of the most pressing issues is the high relapse rate, affecting up to 60% of patients previously treated with CAR-T therapies. Beyond efficacy challenges, innovators struggle with limited indications and eligible patients, the high cost of engineered cell therapy solutions, B cell aplasia and manufacturing challenges. In a roundtable style, companies who are tackling some of these challenges will discuss the future of T cell directed approaches in cancer, and how new applications of CAR-T and other methods can successfully treat more patients. This discussion is increasingly important in a global cancer therapeutics market projected to be worth more than $250B by the year 2030.